Abivax SA ADR ABVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $101.53
- Day Range
- $96.00–105.43
- 52-Week Range
- $5.69–148.83
- Bid/Ask
- $101.30 / $101.62
- Shares Outstanding
- 79.69M
- Market Cap
- $8.09B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 69
- Website
- https://www.abivax.com
Valuation
|
Metric
|
ABVX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ABVX
|
|---|---|
Quick Ratio | 8.07 |
Current Ratio | 8.25 |
Interest Coverage | −11.98 |
Quick Ratio
ABVX
Profitability
|
Metric
|
ABVX
|
|---|---|
Return on Assets (Normalized) | −58.79% |
Return on Equity (Normalized) | −90.74% |
Return on Invested Capital (Normalized) | −72.83% |
Return on Assets
ABVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Krwqszg | Dvwbst | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ksnqzmmdf | Rjdffy | $67B | |||
| argenx SE ADR
ARGX
| Tgrzkrrqb | Dgjh | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fcnszkky | Mdxbth | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Wyggqfflwb | Zfvlxx | $25B | |||
| BioNTech SE ADR
BNTX
| Nmkpnxlw | Kskgh | $22B | |||
| Incyte Corp
INCY
| Wqmtwtmj | Mwqs | $20B | |||
| Moderna Inc
MRNA
| Qmkjsjl | Cqz | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Thhsxfkn | Gwqg | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Jzlynlht | Mlsn | $13B |
United States